Novo Nordisk announced the availability of two new diabetes medications, Ozempic (semaglutide) injection 0.5 mg or 1 mg and Fiasp (insulin aspart injection) 100 Units/mL.
Ozempic is a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Fiasp is a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.
Both medications received approval from the U.S. Food and Drug Administration (FDA) in 2017 and represent the latest advancements to Novo Nordisk's robust diabetes portfolio.
"With 1.5 million new patients diagnosed with diabetes each year,3 we must continue to innovate and bring to market new options to meet the diverse needs of patients," said David Moore, senior vice president, Commercial, Novo Nordisk. "There is no one-size-fits-all approach to effectively managing diabetes and we are proud to add Ozempic and Fiasp to our market-leading portfolio to give patients new treatment options. Our robust portfolio of diabetes products addresses the concerns and needs of people with diabetes, particularly around dosing and administration."
Ozempic is administered once weekly. In clinical trials, Ozempic demonstrated statistically significant A1C reductions. Ozempic is priced at parity to current market-leading weekly GLP-1 receptor agonists, and eligible patients with commercial insurance can use the Ozempic Instant Savings Card to reduce co-pays to as low as $25 per prescription fill for up to two years.
Fiasp is the first fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation. Fiasp should be administered at the beginning of a meal or within 20 minutes after starting a meal due to its appearance in the blood in approximately 2.5 minutes.